Aurobindo Pharma USA, Inc., produces and distributes low-cost generic pharmaceutical drugs to pharmacists and patients in the United States. Some of these products include the group of cephalexin antibiotic oral medications, such as cephalexin capsules, cefdinir capsules and oral suspension, cefuroxime tablets and cefpodoxime proxetil tablets and oral suspension, notes Pharmacy Times.
Aurobindo Pharma USA is a privately owned subsidiary of Aurobindo Pharma Limited with its headquarters in Dayton, New Jersey, states Bloomberg Business. This company received its first abbreviated new drug application, or ANDA, approval from the U.S. government in 2004. Since its foundation, Aurobindo Pharma USA has experienced growth and expansion in its product catalog to include approximately 125 groups of related generic drugs and 450 individual product lines as of 2015, claims Aurobindo Pharma USA.
Aurobindo Pharma USA's activity area encompasses a broad range of therapeutic fields. In 2012, this drug manufacturer released new products, including modafinil tablets, lamivudine and zidovudine tablets, hydrocodone bitartrate and acetaminophen tablets, abacavir sulfate tablets, clopidogrel bisulfate tablets, valsartan and hydrochloride tablets, pioglitazone and metformin tablets, montelukast sodium chewable tablets and oxycodone hydrochloride tablets.
In 2014, Aurobindo Pharma USA issued a voluntary recall throughout the country for one of its products. The recalled batch involved gabapentin capsules with the lot code GESB14011-A. Some capsules in the batch were discovered to be empty, which raised concern over potential side effects from missed dosage of the medication.